Does bacopa improve memory? What the trials show
Bacopa monnieri, sold as Brahmi, is one of the most studied herbal products for memory. Small 12-week trials found modest gains on some word-recall tests, two other trials found none, and most of the research was run with branded extracts supplied or paid for by their makers.
The grade WeakBacopa monnieri extracts for memory in healthy adults
In brief. Bacopa may produce a small improvement in some measures of memory in healthy adults, but the evidence is weak. In a series of small placebo-controlled trials, most of them lasting 12 weeks and using about 300 mg a day of a standardized extract, people taking bacopa did better on some word-list recall tests and no better on most other tests.1315 A 2014 meta-analysis of nine trials reported faster times on two timed attention tasks in its abstract, rather than a pooled memory benefit, but the abstract does not show how many trials entered each estimate.14 Two of the more recent trials, with 72 and 87 participants, found no effect on any cognitive outcome or on their primary outcomes.124 Most trials used branded extracts, and several were funded or supplied by the companies that sell them.811426 Trials in Alzheimer disease are few, small and at high risk of bias.23 The most common side effects are digestive, and products sold as bacopa or Brahmi vary widely in what they contain.943334
Bacopa monnieri is a perennial creeping herb used in Ayurvedic medicine, where it is one of the plants called Brahmi.1633 Its main traditional uses are for memory, insomnia, epilepsy and anxiety, and the triterpenoid saponins known as bacosides are believed to account for most of its pharmacological activity.1 It is sold as a dietary supplement, alone or in multi-ingredient products marketed for brain health.18 This article reviews the randomized trials of bacopa for memory and attention in healthy adults, the smaller literatures on anxiety, dementia and attention deficit hyperactivity disorder (ADHD), and what is known about its safety and about the products themselves.
What is bacopa, and how is it thought to work?
Most of what is known about mechanism comes from animal and cell experiments. A 2013 review summarized the proposed actions as antioxidant protection of neurons, inhibition of acetylcholinesterase (the enzyme that breaks down the neurotransmitter acetylcholine) or activation of choline acetyltransferase (the enzyme that makes it), reduction of β-amyloid, increased cerebral blood flow, and changes in acetylcholine, serotonin and dopamine signaling.2 None of these has been shown to explain an effect in people. In one Thai trial in 60 older adults, plasma acetylcholinesterase activity fell in the bacopa groups.3 In a 2025 Australian trial in 87 adults, bacopa did not change acetylcholinesterase activity, brain-derived neurotrophic factor or a marker of oxidative damage in blood.4
Does bacopa improve memory in healthy adults?
The first chronic trial, published by Stough and colleagues in 2001, randomized 46 healthy adults to 300 mg a day of the KeenMind extract or placebo for 12 weeks. Bacopa improved speed of visual information processing, learning rate and memory consolidation on the Rey Auditory Verbal Learning Test, and state anxiety, with the largest differences at 12 weeks rather than 5.5 Roodenrys and colleagues gave the same extract to 76 adults aged 40 to 65 for three months and found better retention of newly learned word pairs, with no effect on attention, short-term memory, everyday memory questionnaires or anxiety.615 In 2008 Stough’s group reported a 90-day trial in which 62 of 107 enrolled participants completed treatment; bacopa improved spatial working memory accuracy and reduced false alarms on one attention task, while nine other measures in the test battery did not change.715
Three trials in older adults reported similar findings. Calabrese and colleagues randomized 54 people aged 65 or older (mean 73.5 years) in Portland, Oregon, to 300 mg a day or placebo after a six-week placebo run-in; among the 48 who completed, the bacopa group improved on delayed word recall, the primary outcome, and on the Stroop task, with no effect on divided attention or working memory.8 Morgan and Stevens randomized 98 adults over 55 in New South Wales to 300 mg a day of BacoMind; among 81 completers, bacopa improved several word-list learning and delayed recall scores, while a complex figure test, the Trail Making Test and a memory complaint questionnaire did not differ significantly between groups.9 In an Indian trial of 40 people with age-associated memory impairment, of whom 35 finished, 125 mg twice a day for 12 weeks improved mental control, logical memory and paired associate learning.10 A Thai trial of 60 healthy older adults reported better working memory and shorter latencies on event-related potentials with 300 or 600 mg a day for 12 weeks.3 A six-week trial in 60 Indian medical students reported improvements on some cognitive tests.11
Not every trial found a benefit. In a 2013 trial in Bangalore, 72 healthy adults aged 35 to 60 took 450 mg a day or placebo for 12 weeks, and there were no significant differences on any cognitive measure, including verbal learning and memory.12 In 2025 Lopresti and Smith randomized 101 adults aged 40 to 70 with self-reported memory and attention problems to 300 mg a day of the Bacumen extract or placebo for 12 weeks; among 87 completers, there was no difference in verbal learning (P=0.391), attention (P=0.713) or working memory (P=0.610), the primary outcomes.4
What do the systematic reviews conclude?
Pase and colleagues reviewed six 12-week trials in adults without dementia that used three different extracts at 300 to 450 mg a day. Bacopa improved performance on 9 of 17 tests of word-list recall, and there was little evidence of benefit in any other cognitive domain.13 The review’s senior author, Stough, led the 2001 and 2008 KeenMind trials.1357 Kongkeaw and colleagues included nine trials of at least 12 weeks with 518 participants. Their abstract reports shorter Trail Making Test part B times (mean difference −17.9, 95% CI −24.6 to −11.2) and faster choice reaction time (−10.6, −12.1 to −9.2), both labeled as milliseconds, from analyses described as including 437 participants, and interprets these as an effect on speed of attention. The abstract does not state how many trials entered each estimate or whether either figure is an overall or subgroup result, and they judged the trials to be at low risk of bias.14
Later reviews have been more cautious. Neale and colleagues calculated effect sizes for the outcomes that reached significance in each bacopa trial and found values from 0.23 to 1.01, with 0.95 for delayed word recall, but they did not calculate effect sizes for the non-significant outcomes in the same trials, and two of the authors had received funding from Soho Flordis International, whose subsidiary Flordis markets the CDRI 08 extract as KeenMind.1516 A 2021 meta-analysis by Brimson and colleagues found that no two trials in healthy people showed statistically significant changes on the same two tests.17 A 2021 systematic review for the US military’s Consortium for Health and Military Performance concluded that the certainty of evidence for bacopa and eight other supplement ingredients was low and noted that consumers cannot always know what a product contains.18 A 2023 review of herbal and nutritional products in older adults included six bacopa trials among 21 and judged 14 of the 21 to be at high risk of bias overall.19
A 2026 network meta-analysis of 29 trials of bacopa or ginkgo in 2,107 healthy adults reported that bacopa at 600 mg a day or more improved working memory compared with placebo, with a standardized mean difference of 2.03 (95% CI 1.28 to 2.78), and found no difference in sustained attention, selective attention or processing speed.20 An effect of that size is about twice the largest effect Neale and colleagues calculated for any single significant bacopa outcome, and the authors note that the lack of direct comparisons may limit the strength of their evidence.2015 One of the authors was an investigator on the Thai trial that tested 600 mg.203
Does bacopa improve attention or processing speed?
The attention findings are smaller and less consistent than the memory findings. The reductions in Trail Making Test part B and choice reaction times reported in the Kongkeaw abstract were statistically clear in that summary, but small in absolute terms, and the abstract does not show whether they come from the full set of trials or from subgroups.14 Individual trials reported faster inspection time in one study and fewer false alarms on an attention task in another, while other trials found no change in attention.5764 The 2026 network meta-analysis found no effect of bacopa on sustained attention, selective attention or processing speed.20 Two small crossover studies with the CDRI 08 extract, in 24 and 17 healthy volunteers, reported better performance on some cognitive tasks in the hours after a single dose.2122
Does bacopa reduce anxiety or stress?
Anxiety and mood were secondary outcomes in most trials, and results differ. The first Stough trial found lower state anxiety with bacopa.5 In the Calabrese trial, combined state and trait anxiety and depression scores fell in the bacopa group and rose in the placebo group.8 Roodenrys and colleagues found no effect on anxiety, the 2013 Indian trial found only a trend toward lower state anxiety, and the 2025 Australian trial found less self-reported stress reactivity (P=0.03) on a secondary measure.6124 These trials enrolled healthy adults, so their findings do not show that bacopa treats an anxiety disorder.58
Can bacopa help Alzheimer disease or mild cognitive impairment?
The evidence here is thin. A 2022 systematic review found five randomized trials in Alzheimer disease or mild cognitive impairment due to Alzheimer disease. Three tested bacopa in combination with other herbs, two compared it with donepezil, doses ranged from 125 to 500 mg twice a day, and all five were judged to be at high risk of bias. The authors rated the certainty of evidence as very low and found no difference between bacopa and placebo or donepezil.23 The largest single-ingredient comparison with donepezil planned to enroll 48 patients and was stopped after 34 because of slow recruitment and dropouts; after a year there was no difference in the Alzheimer’s Disease Assessment Scale cognitive score.24 A 2024 Iranian trial in 62 people with mild cognitive impairment, using 160 mg a day for two months, reported differences in attention and verbal fluency subscores, inconsistent differences in the total Montreal Cognitive Assessment score across time points, and no effect on sleep quality.25 Bacopa should not be used in place of the evaluation or prescribed treatment of dementia.
Does bacopa help children with ADHD symptoms?
The largest randomized trial in children enrolled 112 boys aged 6 to 14 with high levels of inattention and hyperactivity, gave the CDRI 08 extract or placebo for 14 weeks and analyzed 93. There were no significant differences in behavior, which was the primary question, although a few secondary cognitive, mood and sleep measures favored bacopa.26 The trial was funded by Soho Flordis International.2616 A 2016 review of five pediatric studies of any design by the same research group reported small to medium effects and called for replication with stricter statistical analysis.27 Bacopa is not a substitute for assessment or for prescribed ADHD treatment.
What dose was used in the trials?
Most chronic trials used 300 mg a day of an extract standardized to about 40% to 55% bacosides, taken for 12 weeks. Other doses included 125 mg twice a day, 150 mg twice a day, 450 mg once a day and 600 mg once a day.151011123 In the first trial the differences were larger at 12 weeks than at 5.5 The best dose and duration have not been established.713 The trials tested specific standardized extracts, and their results do not necessarily apply to other products, to raw dried herb or to multi-ingredient blends.
What are the side effects and safety concerns?
Digestive symptoms are the most commonly reported side effect. In the Morgan and Stevens trial, bacopa caused more increased stool frequency, abdominal cramps and nausea than placebo.9 In the 2025 Australian trial, adverse reactions were more frequent with bacopa (P=0.024), mainly digestive complaints and headaches, with no serious events.4 In the Calabrese trial, the number of adverse events possibly related to treatment was similar in the two groups (9 with bacopa and 10 with placebo), and digestive problems were among the most common with bacopa.8 A 30-day open-label safety study of BacoMind in 23 healthy volunteers, run by the manufacturer’s own research staff, found mild gastrointestinal events and no changes in blood tests or electrocardiograms.28 The controlled trials lasted between 6 weeks and 12 months, and a 2013 review noted that long-term toxicity studies in humans had not been done.11242
Drug interactions have been studied only in the laboratory and in animals. In assays of recombinant human enzymes, a standardized bacopa extract inhibited CYP2C19, CYP2C9, CYP1A2 and CYP3A4, which metabolize many prescription drugs.29 In rats, a week of bacopa extract reduced intestinal and liver CYP3A activity and increased exposure to carbamazepine about fourfold.30 No human pharmacokinetic interaction study was found. A published case report described sweating, nausea and a rapid heart rate in a 58-year-old woman taking cevimeline, a cholinergic drug for Sjögren syndrome, after she took a supplement containing bacopa; she recovered when it was stopped.31 One mouse study found that bacopa extract raised thyroxine (T4) by 41%, and there are no human data on thyroid function.32 People who take prescription medicines, including drugs with cholinergic or anticholinergic effects, thyroid medication or drugs with a narrow therapeutic range, should talk with a clinician or pharmacist before starting bacopa, and it should not replace any prescribed medicine.
Are bacopa supplements what the label says?
Often they are not. The name Brahmi is used in India for both Bacopa monnieri and Centella asiatica (gotu kola), which adds to the confusion.33 In a 2023 analysis of Brahmi market samples, only 22.2% to 55.6% tested positive for Brahmi, depending on the method used.33 A 2025 study using a new quantitative PCR test found adulteration, through absent or reduced bacopa content, in 60% of commercial products labeled as bacopa or Brahmi.34 Among seven Brahmi products sold online in Thailand, one contained 3.5 to 7.5 times more bacosides than the other six.35 An Indian study of 12 Ayurvedic formulations containing bacopa found lead, cadmium, chromium and nickel below permissible limits but detected pesticide residues in some samples.36 The positive trials were run with characterized extracts, and a bottle on a shelf may not resemble them.158
How good is the evidence, and who paid for it?
The trials are small, most enrolled fewer than 100 people, and each measured many outcomes, so a benefit on one test among many can arise by chance. Reviews disagree about their quality: the 2014 meta-analysis judged them at low risk of bias, while the 2023 review of older adults and the 2022 dementia review judged most at high risk.141923 Industry involvement is common. The Calabrese trial was funded by the US National Institutes of Health, but MediHerb supplied the tablets at no cost and MediHerb’s director of research was an author, though not involved in conducting or analyzing the study.8 The Kumar trial’s extract and placebo were supplied by Pharmanza Herbal, which makes Bacognize.11 The extract in the Raghav trial was developed and supplied by India’s Central Drug Research Institute, which employed two of the authors and whose bacopa extract has been sold commercially since 1996.1016 The BacoMind safety study was carried out by the manufacturer.28 The two null trials were also industry-supported: the 2013 Indian trial by Hindustan Unilever, which sold two Brahmi products, and the 2025 Australian trial by US Pharma Lab, which supplied the product.124 The pediatric ADHD trial was funded by Soho Flordis International.26 We could not find funding statements for the 2001 and 2008 KeenMind trials or the Morgan and Stevens trial in the sources available to us.579
What remains uncertain?
It is not known whether the small test-score differences translate into any noticeable improvement in daily memory; the trials that measured everyday memory complaints found no difference.69 None of the adult trials reviewed here randomized more than about 110 people, and several were funded or supplied by manufacturers. The best dose is unclear, and there are no controlled human studies of drug interactions or thyroid effects.132932
Evidence grades
The grades below are Thryval editorial judgments based on the studies cited in this article. The grading rules are set out on our Research page.
Frequently asked questions
Does bacopa really improve memory?
Possibly, by a small amount on some tests. About eight small trials reported better word-list learning or delayed recall after about 12 weeks, but two other trials found no effect and reviews rate the certainty of evidence as low.1312418
How long does bacopa take to work?
The chronic trials lasted 12 weeks, and in the first trial the differences were larger at 12 weeks than at 5 weeks. No trial has compared durations directly.5 Two small studies reported effects on some tasks within hours of a single dose.2122
What dose of bacopa was used in studies?
Most trials used 300 mg a day of an extract standardized to about 40% to 55% bacosides; others used 250 to 600 mg a day.15103
What are the side effects of bacopa?
Digestive symptoms such as nausea, abdominal cramps and more frequent stools are the most common, and headaches were also reported in one trial.94
Can bacopa interact with medications?
Laboratory and rat studies show that bacopa extract inhibits several liver enzymes that metabolize drugs, and one case report described a possible interaction with cevimeline. There are no human interaction studies, so anyone taking prescription medicines should check with a clinician or pharmacist first.293031
Is Brahmi the same as bacopa?
Not always. The name Brahmi is used for both Bacopa monnieri and Centella asiatica (gotu kola), and market analyses have found many Brahmi products with little or no bacopa.3334
Implications for patients and clinicians
For a healthy adult who wants to try bacopa for memory, the trials suggest at best a small effect on some memory tests after about three months, at the cost of possible digestive side effects, and the evidence comes mostly from small trials of specific branded extracts.1394 Product quality is a real problem, and an extract standardized for bacoside content is closer to what was studied than an unlabeled Brahmi powder.333415 People taking prescription medicines should check for interactions first.29 New or worsening memory problems call for medical evaluation, and bacopa should not replace treatment for dementia, ADHD or any other condition. Readers interested in another supplement studied for memory can find our review of creatine and brain function.
This article is for education and is not medical advice.
References
-
Walker EA, Pellegrini MV. Bacopa monnieri. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023 (updated March 17, 2023). Clinical review; authors declared no relevant financial relationships. PubMed 36943953 ↩
-
Aguiar S, Borowski T. Neuropharmacological review of the nootropic herb Bacopa monnieri. Rejuvenation Res. 2013;16(4):313–326. Narrative review of animal, in vitro and human studies. PMC3746283 · PubMed 23772955 ↩↩
-
Peth-Nui T, Wattanathorn J, Muchimapura S, et al. Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evid Based Complement Alternat Med. 2012;2012:606424. Randomized controlled trial, n=60, 300 or 600 mg/day; supported in part by the National Research Council of Thailand and Khon Kaen University. PMC3537209 · PubMed 23320031 ↩↩↩↩↩
-
Lopresti AL, Smith SJ. The effects of a Bacopa monnieri extract (Bacumen) on cognition, stress, and fatigue in healthy adults: a randomized, double-blind, placebo-controlled trial. Clin Drug Investig. 2025;45(12):967–982. Randomized controlled trial, n=101 (87 completed); funded by US Pharma Lab, which supplied the product and placebo and was not involved in data collection or interpretation; first author directs a contract research organization funded by nutraceutical companies. PubMed 41091332 ↩↩↩↩↩↩↩↩↩↩↩↩↩↩↩
-
Stough C, Lloyd J, Clarke J, et al. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001;156(4):481–484. Randomized controlled trial, n=46, KeenMind 300 mg/day; funding statement not available in the abstract or publisher record. PubMed 11498727 ↩↩↩↩↩↩↩↩↩
-
Roodenrys S, Booth D, Bulzomi S, et al. Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology. 2002;27(2):279–281. Randomized controlled trial, n=76, KeenMind 300–400 mg/day. PubMed 12093601 ↩↩↩↩↩
-
Stough C, Downey LA, Lloyd J, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008;22(12):1629–1634. Randomized controlled trial, 107 enrolled, 62 completed, KeenMind 300 mg/day. PubMed 18683852 ↩↩↩↩↩
-
Calabrese C, Gregory WL, Leo M, et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008;14(6):707–713. Randomized controlled trial, n=54 (48 completed); funded by the NIH National Center for Complementary and Alternative Medicine and the Northwest Health Foundation; MediHerb supplied the tablets at no cost, and author K. Bone was MediHerb’s chairman and director of research. PMC3153866 · PubMed 18611150 ↩↩↩↩↩↩↩↩↩
-
Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebo-controlled, double-blind trial. J Altern Complement Med. 2010;16(7):753–759. Randomized controlled trial, n=98 (81 completed), BacoMind (Natural Remedies) 300 mg/day; funding statement not available in the abstract or publisher record. PubMed 20590480 ↩↩↩↩↩↩↩↩
-
Raghav S, Singh H, Dalal PK, Srivastava JS, Asthana OP. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Indian J Psychiatry. 2006;48(4):238–242. Randomized controlled trial, n=40 (35 completed), 125 mg twice daily; extract developed and supplied by the Central Drug Research Institute, Lucknow, which employed two authors. PMC2915594 · PubMed 20703343 ↩↩↩↩
-
Kumar N, Abichandani LG, Thawani V, et al. Efficacy of standardized extract of Bacopa monnieri (Bacognize) on cognitive functions of medical students: a six-week, randomized placebo-controlled trial. Evid Based Complement Alternat Med. 2016;2016:4103423. Randomized controlled trial, n=60, 150 mg twice daily; extract and placebo supplied at no cost by Pharmanza Herbal; authors declared no conflicts. PMC5075615 · PubMed 27803728 ↩↩↩↩↩
-
Sathyanarayanan V, Thomas T, Einöther SJ, et al. Brahmi for the better? New findings challenging cognition and anti-anxiety effects of Brahmi (Bacopa monniera) in healthy adults. Psychopharmacology (Berl). 2013;227(2):299–306. Randomized controlled trial, n=72, 450 mg/day; supported by Hindustan Unilever, which had two Brahmi products on the market; three authors were Unilever employees. PubMed 23354535 ↩↩↩↩↩↩↩↩
-
Pase MP, Kean J, Sarris J, et al. The cognitive-enhancing effects of Bacopa monnieri: a systematic review of randomized, controlled human clinical trials. J Altern Complement Med. 2012;18(7):647–652. Systematic review: 6 trials. PubMed 22747190 ↩↩↩↩↩↩↩↩
-
Kongkeaw C, Dilokthornsakul P, Thanarangsarit P, Limpeanchob N, Norman Scholfield C. Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. J Ethnopharmacol. 2014;151(1):528–535. Meta-analysis: 9 trials, 518 participants. PubMed 24252493 ↩↩↩↩↩
-
Neale C, Camfield D, Reay J, Stough C, Scholey A. Cognitive effects of two nutraceuticals Ginseng and Bacopa benchmarked against modafinil: a review and comparison of effect sizes. Br J Clin Pharmacol. 2013;75(3):728–737. Review with effect-size calculations; two authors had received funding from Soho Flordis International. PMC3575939 · PubMed 23043278 ↩↩↩↩↩↩↩↩↩↩
-
Kean JD, Kaufman J, Lomas J, et al. A randomized controlled trial investigating the effects of a special extract of Bacopa monnieri (CDRI 08) on hyperactivity and inattention in male children and adolescents: BACHI study protocol. Nutrients. 2015;7(12):9931–9945. Trial protocol, describing the history of the CDRI extract and its marketing by Flordis as KeenMind; funded by Soho Flordis International Research. PMC4690059 · PubMed 26633481 ↩↩↩↩
-
Brimson JM, Brimson S, Prasanth MI, et al. The effectiveness of Bacopa monnieri (Linn.) Wettst. as a nootropic, neuroprotective, or antidepressant supplement: analysis of the available clinical data. Sci Rep. 2021;11(1):596. Systematic review and meta-analysis; no competing interests declared. PMC7803732 · PubMed 33436817 ↩
-
Crawford C, Boyd C, Deuster PA. Dietary supplement ingredients for optimizing cognitive performance among healthy adults: a systematic review. J Altern Complement Med. 2021;27(11):940–958. Systematic review: 9 ingredients, 69 publications. PubMed 34370563 ↩↩↩↩
-
Cave AE, Chang DH, Münch GW, Steiner-Lim GZ. A systematic review of the safety and efficacy on cognitive function of herbal and nutritional medicines in older adults with and without subjective cognitive impairment. Syst Rev. 2023;12(1):143. Systematic review: 21 trials, 6 of bacopa. PMC10433666 · PubMed 37592293 ↩↩
-
Tiemtad P, Ingkaninan K, Temkitthawon P, et al. Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: a systematic review and network meta-analysis. Phytomedicine. 2026;153:157915. Network meta-analysis: 29 trials, 2,107 participants; funded by the Thailand Research Fund; no competing interests declared. PubMed 41678913 ↩↩↩↩↩
-
Downey LA, Kean J, Nemeh F, et al. An acute, double-blind, placebo-controlled crossover study of 320 mg and 640 mg doses of a special extract of Bacopa monnieri (CDRI 08) on sustained cognitive performance. Phytother Res. 2013;27(9):1407–1413. Crossover trial, n=24. PubMed 23281132 ↩↩
-
Benson S, Downey LA, Stough C, et al. An acute, double-blind, placebo-controlled cross-over study of 320 mg and 640 mg doses of Bacopa monnieri (CDRI 08) on multitasking stress reactivity and mood. Phytother Res. 2014;28(4):551–559. Crossover trial, n=17. PubMed 23788517 ↩↩
-
Basheer A, Agarwal A, Mishra B, et al. Use of Bacopa monnieri in the treatment of dementia due to Alzheimer disease: systematic review of randomized controlled trials. Interact J Med Res. 2022;11(2):e38542. Systematic review: 5 trials, all at high risk of bias; no conflicts declared. PMC9379783 · PubMed 35612544 ↩↩↩↩↩
-
Prabhakar S, Vishnu VY, Modi M, et al. Efficacy of Bacopa monnieri (Brahmi) and donepezil in Alzheimer’s disease and mild cognitive impairment: a randomized double-blind parallel phase 2b study. Ann Indian Acad Neurol. 2020;23(6):767–773. Randomized controlled trial, n=34 (stopped early); intramural funding, PGIMER Chandigarh. PMC7900738 · PubMed 33688125 ↩↩↩
-
Delfan M, Kordestani-Moghaddam P, Gholami M, Kazemi K, Mohammadi R. Evaluating the effects of Bacopa monnieri on cognitive performance and sleep quality of patients with mild cognitive impairment: a triple-blinded, randomized, placebo-controlled trial. Explore (NY). 2024;20(5):102990. Randomized controlled trial, n=62, 160 mg/day for 2 months. PubMed 38538390 ↩
-
Kean JD, Downey LA, Sarris J, et al. Effects of Bacopa monnieri (CDRI 08) in a population of males exhibiting inattention and hyperactivity aged 6 to 14 years: a randomized, double-blind, placebo-controlled trial. Phytother Res. 2022;36(2):996–1012. Randomized controlled trial, 112 enrolled, 93 analyzed; funded by Soho Flordis International. PubMed 35041248 ↩↩↩↩↩↩
-
Kean JD, Downey LA, Stough C. A systematic review of the Ayurvedic medicinal herb Bacopa monnieri in child and adolescent populations. Complement Ther Med. 2016;29:56–62. Systematic review: 5 studies of any design. PubMed 27912958 ↩
-
Pravina K, Ravindra KR, Goudar KS, et al. Safety evaluation of BacoMind in healthy volunteers: a phase I study. Phytomedicine. 2007;14(5):301–308. Open-label dose-escalation study, n=23, 30 days; conducted by the R&D Centre of Natural Remedies, maker of BacoMind. PubMed 17442556 ↩↩
-
Ramasamy S, Kiew LV, Chung LY. Inhibition of human cytochrome P450 enzymes by Bacopa monnieri standardized extract and constituents. Molecules. 2014;19(2):2588–2601. In vitro recombinant enzyme study; no conflicts declared. PMC6271976 · PubMed 24566323 ↩↩↩↩↩
-
Singh R, Panduri J, Kumar D, et al. Evaluation of memory enhancing clinically available standardized extract of Bacopa monniera on P-glycoprotein and cytochrome P450 3A in Sprague-Dawley rats. PLoS One. 2013;8(8):e72517. Animal study. PMC3756011 · PubMed 24015255 ↩↩↩
-
Acquarulo B, Tandon P, Macica CM. Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report. J Med Case Rep. 2022;16(1):253. Case report. PMC9241182 · PubMed 35765109 ↩↩↩
-
Kar A, Panda S, Bharti S. Relative efficacy of three medicinal plant extracts in the alteration of thyroid hormone concentrations in male mice. J Ethnopharmacol. 2002;81(2):281–285. Animal study. PubMed 12065164 ↩↩↩
-
Shah AP, Travadi T, Sharma S, et al. Comprehensive analysis using DNA metabarcoding, SCAR marker based PCR assay, and HPLC unveils the adulteration in Brahmi herbal products. Mol Biol Rep. 2023;50(9):7605–7618. Laboratory analysis of market products; funded by the Gujarat State Biotechnology Mission. PubMed 37532919 ↩↩↩↩↩↩↩
-
Biltes R, Villa C, Costa J, Mafra I. Exploiting marker genes for reliable botanical authentication of Bacopa monnieri products. Foods. 2025;14(18):3275. Laboratory method development and analysis of commercial products; funded by Fundação para a Ciência e a Tecnologia; no conflicts declared. PMC12469326 · PubMed 41008247 ↩↩↩↩↩
-
Nopparat J, Sujipuli K, Ratanasut K, et al. Exploring the excellence of commercial Brahmi products from Thai online markets: unraveling phytochemical contents, antioxidant properties and DNA damage protection. Heliyon. 2024;10(2):e24509. Laboratory analysis of 7 products; no competing interests declared. PMC10831600 · PubMed 38304802 ↩↩
-
Mishra A, Mishra AK, Tiwari OP, Jha S. Studies on metals and pesticide content in some Ayurvedic formulations containing Bacopa monnieri L. J Integr Med. 2016;14(1):44–50. Laboratory analysis of 12 products. PubMed 26778228 ↩


